Entero Therapeutics Pre-Tax Income 2015-2024 | ENTO

Entero Therapeutics pre-tax income from 2015 to 2024. Pre-tax income can be defined as company's earnings or loss before taxes on income have been accounted for.

Entero Therapeutics Pre-Tax Income 2015-2024 | ENTO

Entero Therapeutics pre-tax income from 2015 to 2024. Pre-tax income can be defined as company's earnings or loss before taxes on income have been accounted for.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$171.5B
Vertex Pharmaceuticals (VRTX)$119.5B
Regeneron Pharmaceuticals (REGN)$114.6B
Gilead Sciences (GILD)$103.4B
Bristol Myers Squibb (BMY)$101.6B
CSL (CSLLY)$97.4B
GSK (GSK)$84.8B
Alnylam Pharmaceuticals (ALNY)$35.2B
Argenex SE (ARGX)$31.4B
Biogen (BIIB)$28.2B
BioNTech SE (BNTX)$28B
Moderna (MRNA)$24.6B
Illumina (ILMN)$21.1B
BeiGene (BGNE)$20.7B
Genmab (GMAB)$16B
BioMarin Pharmaceutical (BMRN)$13.3B
Exact Sciences (EXAS)$12.6B
Incyte (INCY)$12.5B
Insmed (INSM)$12.5B
Vaxcyte (PCVX)$12.4B
Bio-Techne Corp (TECH)$12.4B
Sarepta Therapeutics (SRPT)$11.9B
QIAGEN (QGEN)$10.3B
Bio-Rad Laboratories (BIO.B)$9.1B
Ascendis Pharma (ASND)$8.6B
Roivant Sciences (ROIV)$8.6B
Legend Biotech (LEGN)$8.5B
Repligen (RGEN)$8.2B
Intra-Cellular Therapies (ITCI)$7.7B
Exelixis (EXEL)$7.5B